Celltrion Receives Approval for Phase 3 Clinical Trial Plan on European Interchangeability of Uplizna
[Asia Economy Reporter Minji Lee] Celltrion announced on the 4th that it has received approval for a Phase 3 clinical trial plan comparing the pharmacokinetics and efficacy of Uplima (CT-P17, Humira biosimilar) and Humira in patients with severe plaque psoriasis.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- Court Partially Grants Samsung Electronics' Injunction to Prohibit Industrial Action... 100 Million Won Penalty Per Day for Violations
- [US-China Summit] China to Purchase $17 Billion in US Agricultural Products Annually...Real Gains for Beijing
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The company explained, "In addition to the product approval for all indications approved for Humira, by further proving interchangeability, we expect to increase market share in the large U.S. market."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
